A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension

Circulation Journal

Volumn 75, Issue 3, 2011, Pages 677-682

  Satoh, Tohru ^a   Saji, Tsutomu ^b   Watanabe, Hiroshi ^c   Ogawa, Satoshi ^d   Takehara, Kazuhiko ^e   Tanabe, Nobuhiro ^f   Yamada, Norikazu ^g   Yao, Atsushi ^h   Miyaji, Katsumasa ⁱ   Nakanishi, Norifumi ^k   Suzuki, Yumiko ^j   Fujiwara, Tadami ^j   Kuriyama, Takayuki ^f  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KEIO UNIVERSITY HOSPITAL   (Japan)

^e KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^f CHIBA UNIVERSITY HOSPITAL   (Japan)

^g MIE UNIVERSITY HOSPITAL   (Japan)

^h UNIVERSITY OF TOKYO HOSPITAL   (Japan)

ⁱ National Hospital Organization   (Japan)

^j PFIZER INC   (United States)

^k NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

more..

Author keywords

Efficacy; Pharmacokinetics; Pulmonary arterial hypertension; Safety; Sildenafil

Indexed keywords

BERAPROST; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CARDIOTONIC AGENT; DIURETIC AGENT; OXYGEN; SILDENAFIL; WARFARIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; FUNCTIONAL ASSESSMENT; HEMODYNAMICS; HUMAN; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OXYGEN THERAPY; PHASE 3 CLINICAL TRIAL; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SCORING SYSTEM; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; WALKING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; JAPAN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PIPERAZINES; PURINES; SULFONES; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATOR AGENTS; WALKING; YOUNG ADULT;

EID: 79952319855     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0671     Document Type: Article

References (28)

1. Ruiz MJ, Escribano P, Delgado JF, Jiménez C, Tello R, Gómez MA, et al. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. J Heart Lung Transplant 2006; 25: 1353-1357.
2. Kähler CM, Colleselli D. Pulmonary arterial hypertension (PAH) in connective tissue diseases. Rheumatology 2006; 45: 11-13.
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
4. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
5. Nakano T, Aoyanagi S, Kawai A, Kuriyama T, Kobayashi M, Saji T, et al. Guideline for treatment of pulmonary hypertension. Jpn Circ J 2001; 65(Suppl. 5): 1077-1118.
6. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: 43-54.
7. Japan Intractable Diseases Information Center. Numbers of Certificates of Specified Disease Treatment Beneficiaries in 2004. http://www.nanbyou.or.jp (accessed July 12, 2010).
8. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
9. Guilluy C, Sauzeau V, Rolli-Derkinderen M, Guérin P, Sagan C, Pacaud P, et al. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 2005; 146: 1010-1018.
10. Watanabe H. Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 2009; 73: 1597-1598.
11. Doe Z, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 2009; 73: 1731-1739.
12. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-2069.
13. Galiè N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 81S-88S.11.
14. Rubin LJ. Pulmonary arterial hypertension. Proc Am Thorac Soc 2006; 3: 111-115.
15. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83: 35-44.
16. Dishy V, Sofowora G, Harris PA, Kandcer M, Zhan F, Wood AJ, et al. The effect of sildenafil on nitric oxide-induced vasodilation in healthy men. Clin Pharmacol Ther 2001; 70: 270-279.
17. Krenzelok EP, Krenzelok E. Sildenafil: Clinical toxicology profile. Clin Toxicol 2000; 38: 7645-7651.
18. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622-1626.
19. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43: 1149-1153.
20. Breavo JA. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Pysiol Rev 1995; 75: 725-748.
21. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-165.
22. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 2008; 118: 1486-1495.
23. Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest 1998; 114: 225S-230S.
24. Wheeler W, Hayes S, Nguyen N, Cilla AM, Rybowicz J, Jones CC, et al. Sildenafil: A possible treatment for acute pulmonary hypertension during cardiac surgery. BUMC Proc 2002; 15: 13-15.
25. Black SM, Sanchez LS, Mata-Greenwood E, Bekker JM, Steinhorn RH, Fineman JR. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001; 281: L1051-L1057.
26. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.
27. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
28. Vizza CD, Sciomer S, Morelli S, Lavalle C, Di Marzio P, Padovani D, et al. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 2001; 86: 661-665.